From: PNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients
 | Patients with HCC | Patients without HCC | Comparison between patients with HCC and those without HCC | Multiple regression analysis for factors associated with HCC development | |
---|---|---|---|---|---|
(n = 48) | (n = 183) | Odds ratio (95% confidence interval) | p | ||
Age (yrs) | 70.5 ± 7.8 | 60.9 ± 11.2 | p < 0.0001 | 1.12 (1.07 - 1.17) | p < 0.0001 |
Gender (male/female) | 25/23 | 78/105 | NS | 1.83 (0.90 - 3.71) | p = 0.0936 |
BMI (kg/m2) | 23.1 ± 3.9 | 22.3 ± 3.4 | NS |  |  |
Response to IFN treatment (NVR/no past IFN therapy) | 17/31 | 77/106 | NS | Â | Â |
PNPLA3 (GG/CC・CG) | 34/14 | 156/27 | p = 0.0200 | 2.62 (1.15 - 5.96) | p = 0.0218 |
AST (IU/L) | 72.1 ± 54.8 | 53.0 ± 46.4 | p = 0.0158 |  |  |
ALT (IU/L) | 60.4 ± 46.4 | 63.5 ± 82.1 | NS |  |  |
γ-GTP (IU/L) | 50.4 ± 34.9 | 61.1 ± 85.8 | NS |  |  |
Albumin (g/dL) | 3.5 ± 0.7 | 4.2 ± 0.5 | p < 0.0001 |  |  |
Total bilirubin (mg/dL) | 1.3 ± 0.97 | 0.9 ± 0.76 | p = 0.0010 |  |  |
Platelet count (x104/μL) | 9.5 ± 4.2 | 14.4 ± 5.4 | p < 0.0001 |  |  |
Prothrombin time (%) | 83.7 ± 13.90 | 97.1 ± 18.8 | p < 0.0001 |  |  |
Hyaluronic acid (ng/mL) | 473.8 ± 480.9 | 181.1 ± 267.2 | p < 0.0001 |  |  |
α-fetoprotein (ng/mL) | 308.6 ± 1134.9 | 20.8 ± 113.2 | p = 0.0009 |  |  |
PIVKA-II(mAU/mL) | 40.25 ± 43.22 | 20.56 ± 9.93 | p = 0.0030 |  |  |
HCV genotype (1/2/3) | 42/6/0 | 169/35/2 | NS | Â | Â |
HCV RNA (log IU/mL) | 6.0 ± 1.1 | 6.2 ± 1.0 | NS |  |  |
Velocity of shear wave (m/s) | 2.19 ± 0.64 | 1.57 ± 0.52 | p < 0.0001 |  |  |